Savaysa

TABLE OF CONTENTS

4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 Savaysa : Stroke prevention in atrial fibrillation (SPAF)
20 Savaysa : Venous thromboembolism (VTE)

LIST OF FIGURES
13 Figure 1: Savaysa for SPAF – SWOT analysis
14 Figure 2: Datamonitor Healthcare’s drug assessment summary of Savaysa for SPAF
15 Figure 3: Datamonitor Healthcare’s drug assessment summary of Savaysa for SPAF
17 Figure 4: Savaysa sales for SPAF across the US, Japan, and five major EU markets, by country, 2017–26
26 Figure 5: Savaysa for venous thromboembolism – SWOT analysis
27 Figure 6: Datamonitor Healthcare’s drug assessment summary of Savaysa for venous thromboembolism
28 Figure 7: Datamonitor Healthcare’s drug assessment summary Savaysa for venous thromboembolism
30 Figure 8: Savaysa sales forecast for VTE in the US, Japan, and five major EU markets, by country, 2017–26

LIST OF TABLES
5 Table 1: Savaysa drug profile
7 Table 2: Savaysa pivotal trial data in SPAF
9 Table 3: Savaysa late-phase trial data in SPAF
11 Table 4: Savaysa ongoing late-phase clinical trials in SPAF
18 Table 5: Savaysa sales for SPAF across the US, Japan, and five major EU markets, by country ($m), 2017–26
20 Table 6: Savaysa drug profile
22 Table 7: Savaysa pivotal trial data in venous thromboembolism
24 Table 8: Savaysa late-phase trial data in venous thromboembolism
25 Table 9: Savaysa ongoing late-phase clinical trial in venous thromboembolism
31 Table 10: Savaysa sales for VTE in the US, Japan, and five major EU markets, by country ($m), 2017–26